Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) and argenx (NASDAQ:ARGX – Get Free Report) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, institutional ownership and earnings.
This table compares Neurocrine Biosciences and argenx’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations and price targets for Neurocrine Biosciences and argenx, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation & Earnings
This table compares Neurocrine Biosciences and argenx’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Neurocrine Biosciences||$1.67 billion||6.84||$154.50 million||$1.73||67.69|
|argenx||$445.27 million||68.60||-$709.59 million||($7.17)||-72.77|
Neurocrine Biosciences has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Neurocrine Biosciences has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.
Institutional and Insider Ownership
93.5% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 52.8% of argenx shares are held by institutional investors. 4.4% of Neurocrine Biosciences shares are held by insiders. Comparatively, 2.4% of argenx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Neurocrine Biosciences beats argenx on 10 of the 14 factors compared between the two stocks.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.